FANZCAP (Compound., Research) PhD candidate MPhil BPharm Senior Project and Policy Officer, Training, Education and Regulatory Compliance for Advanced Therapeutics | Advanced Therapeutics | OHMR Ms. Kerry Watts is a consultant pharmacist and Senior Project and Policy Officer for Advanced Therapeutics at the NSW Health Ministry Office for Health and Medical Research. She is a PhD candidate and holds an MPhil in anticoagulation. Kerry is also an Advanced Australia Pharmacy (AdPha) Fellow and Co-Chair of the AdPha Compounding Leadership Committee. As the author of the NSW Health Policy Directive on the Preparation of Pharmaceutical and Advanced Therapeutic Products, Kerry collaborates closely with researchers and national regulatory bodies to expedite the regulation and translation of advanced therapeutics. She also supports health system preparedness to deliver these advanced therapeutics to patients as standard care.

Dr Ruby Lin is an Adjunct Professor in Genomics and Deputy Director of Phage Australia, where she leads multi stakeholder programs bridging science, policy, and innovation to accelerate the clinical translation of phage therapy. As one of the chief architects of Australia’s integrated phage therapy platform — encompassing national biobanking, genomics pipelines, and clinical coordination — she played a pivotal role in enabling the Standardised Treatment and Monitoring Protocol (STAMP). This platform delivers personalised, regulatory ready solutions to address antimicrobial resistance and supports scalable implementation across healthcare systems.

Branwen Morgan PhD has held numerous senior roles that bridge academic institutions, government, publicly listed companies, and not-for-profit organisations. Branwen’s journey from molecular biologist to journalist, consultant, and influential science leader in antimicrobial resistance exemplifies the power and flexibility of a portfolio-based career in the life sciences sector. She is based at CSIRO where she formerly led the Minimising Antimicrobial Resistance (AMR) Mission. Together with her team, she significantly improved the visibility of AMR amongst policymakers, created new industry, research, and government connections, and catalysed millions of dollars of investment into antimicrobial resistance research. Their work emphasises the interconnections between antimicrobial use and resistance across the human, animal, and environmental sectors, addressing research implementation and policy barriers. She is an adjunct Professor at the University of Technology Sydney.

Andrew Care is an Associate Professor at the University of Technology Sydney (UTS) and Director of the Biologics Innovation Facility (BIF), a GMP-like pilot plant for biopharmaceutical production. His research spans synthetic biology, nanomedicine, and biomanufacturing, with a focus on nanoparticle-based platforms for drug delivery and vaccinology. Andrew leads strategic and operational activities at BIF, including R&D, contract manufacturing, and workforce training. He plays an active role in developing Australia’s much-needed GMP manufacturing workforce, serving as Director of GMP Training within the NSW RNA Research & Training Network (NSW RRTN), and contributing to national skills strategy via AusBiotech’s Catalyst Workforce Development Group and the NSW Government’s GMP Future Workforce Roundtable.

Sophie Stocker is an Associate Professor at the School of Pharmacy, Sydney University, and holds appointments at St Vincent’s Hospital and Westmead Hospital, Sydney, Australia. Her career is distinguished by a diverse experience spanning industry, healthcare and academia, which uniquely positions her to address the complexities of patient care. A/Prof Stocker’s research focuses on understanding variability in response to medicines and developing strategies to manage this variability to optimise patient care. She applies her expertise across multiple disciplines, including clinical pharmacology, pharmacogenomics, pharmacometrics, health service delivery and qualitative research to optimise medicine use across several therapeutic areas including anti-infectives, gout, diabetes and transplantation. Nationally and internationally recognised for her leadership in the implementation of precision dosing software and other precision medicine approaches, A/Prof Stocker has made significant contributions to advancing individualised patient care. She has co-authored more than 120 papers and holds several committee positions in key scientific societies. Her leadership has been acknowledged nationally and internationally through prestigious awards, including the Victor Armstrong Young Investigator Award (2022), and the CERTARA Young Investigator and the APSA Emerging Leader Award (2020).